Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VOR Stock Forecast 2026-2027
$14.15
Current Price
$296.23M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VOR Price Targets
+288.7%
To High Target of $55.00
+225.1%
To Median Target of $46.00
+126.1%
To Low Target of $32.00
VOR Price Momentum
+21.3%
1 Week Change
+13.1%
1 Month Change
-48.4%
1 Year Change
+8.2%
Year-to-Date Change
-78.5%
From 52W High of $65.80
+440.1%
From 52W Low of $2.62
📊 TOP ANALYST CALLS
Did VOR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vor Biopharma is one of their latest high-conviction picks.
Latest VOR Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, VOR has a bullish consensus with a median price target of $46.00 (ranging from $32.00 to $55.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $14.15, the median forecast implies a 225.1% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 126.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VOR Analyst Ratings
6
Buy
1
Hold
0
Sell
VOR Price Target Range
Low
$32.00
Average
$46.00
High
$55.00
Current: $14.15
Latest VOR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VOR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Citigroup | Geoff Meacham | Buy | Initiates | $50.00 |
| Dec 19, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $40.00 |
| Dec 17, 2025 | TD Cowen | Yaron Werber | Buy | Initiates | $N/A |
| Dec 9, 2025 | JP Morgan | Anupam Rama | Overweight | Initiates | $43.00 |
| Nov 25, 2025 | Wedbush | Martin Fan | Neutral | Assumes | $9.00 |
| Nov 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $32.00 |
| Oct 29, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $52.00 |
| Oct 15, 2025 | Baird | Jack Allen | Outperform | Upgrade | $64.00 |
| Aug 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $3.00 |
| Jun 30, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Upgrade | $3.00 |
| Jun 27, 2025 | Baird | Jack Allen | Neutral | Maintains | $1.00 |
| Jun 26, 2025 | Wedbush | David Nierengarten | Neutral | Reiterates | $0.40 |
| May 9, 2025 | JMP Securities | Silvan Tuerkcan | Market Perform | Downgrade | $6.00 |
| May 9, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Neutral | Downgrade | $N/A |
| Mar 21, 2025 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $8.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $13.00 |
| Mar 21, 2025 | Stifel | Stephen Willey | Buy | Maintains | $5.00 |
| Dec 10, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $12.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
| Nov 8, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
Vor Biopharma Inc. (VOR) Competitors
The following stocks are similar to Vor Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vor Biopharma Inc. (VOR) Financial Data
Vor Biopharma Inc. has a market capitalization of $296.23M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -120.9%.
Valuation Metrics
Market Cap
$296.23M
Enterprise Value
$-26,651,282
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+115.7%
Current Ratio
9.2x
Debt/Equity
0.0x
ROE
-120.9%
ROA
-144.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vor Biopharma Inc. (VOR) Business Model
About Vor Biopharma Inc.
What They Do
Develops engineered stem cell therapies for cancer.
Business Model
Vor Biopharma Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing engineered hematopoietic stem cells (eHSCs) combined with targeted therapies to treat hematological malignancies. The company generates revenue through ongoing research, clinical trials, and eventually aims to commercialize its innovative therapies for cancer treatment.
Additional Information
Vor Biopharma's proprietary platform enhances cell graft compatibility and efficacy, aiming to reduce adverse effects of traditional cancer treatments. The company is positioned at the forefront of genetic engineering and targeted therapeutics, which are key trends in the rapidly evolving biotech industry. Its commitment to pioneering advancements in personalized medicine could yield significant implications for future developments in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
154
CEO
Dr. Jean-Paul Kress M.D.
Country
United States
IPO Year
2001
Website
www.vorbio.comVor Biopharma Inc. (VOR) Latest News & Analysis
Latest News
Quick Summary
Vor Bio (Nasdaq: VOR) will present and host 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, focusing on autoimmune disease treatments.
Why It Matters
Vor Bio's participation at a major healthcare conference signals potential investor interest and highlights its progress in autoimmune disease treatment, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
20 days ago
Quick Summary
Vor Biopharma Inc. appointed Andrew Levin and Wouter Joustra to its Board of Directors following a $150M PIPE financing involving both investors.
Why It Matters
The appointments of experienced board members and the $150M PIPE financing signal confidence in Vor Biopharma's growth potential, which may enhance investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vor Bio Announces $150 Million Private Placement
28 days ago
Quick Summary
Vor Bio (Nasdaq: VOR) plans to raise approximately $150 million through a private placement of 13.9 million shares at $10.81 each. The deal is set to close around December 18, 2025.
Why It Matters
Vor Bio's $150 million private placement indicates strong institutional interest and funding for its autoimmune disease treatments, potentially enhancing growth prospects and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vor Biopharma (VOR) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may lead to a rise in its stock price.
Why It Matters
Vor Biopharma's upgrade to a Zacks Rank #2 signals increased confidence in its earnings potential, likely attracting more investors and potentially driving up the stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Telitacicept shows strong late-stage data in autoimmune diseases. The company is enhancing its executive leadership and board to improve global development capabilities.
Why It Matters
Positive late-stage data for Telitacicept across autoimmune diseases suggests strong market potential and growth opportunities, while enhanced leadership indicates a commitment to global expansion.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
2 months ago
Quick Summary
Vor Biopharma Inc. (NASDAQ:VOR) has priced a public offering of 10 million shares at $10.00 each.
Why It Matters
Vor Biopharma's public offering at $10.00 per share could raise significant capital, impacting its financial position and investor sentiment, potentially affecting stock performance.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About VOR Stock
What is Vor Biopharma Inc.'s (VOR) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Vor Biopharma Inc. (VOR) has a median price target of $46.00. The highest price target is $55.00 and the lowest is $32.00.
Is VOR stock a good investment in 2026?
According to current analyst ratings, VOR has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VOR stock?
Wall Street analysts predict VOR stock could reach $46.00 in the next 12 months. This represents a 225.1% increase from the current price of $14.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vor Biopharma Inc.'s business model?
Vor Biopharma Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing engineered hematopoietic stem cells (eHSCs) combined with targeted therapies to treat hematological malignancies. The company generates revenue through ongoing research, clinical trials, and eventually aims to commercialize its innovative therapies for cancer treatment.
What is the highest forecasted price for VOR Vor Biopharma Inc.?
The highest price target for VOR is $55.00 from at , which represents a 288.7% increase from the current price of $14.15.
What is the lowest forecasted price for VOR Vor Biopharma Inc.?
The lowest price target for VOR is $32.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 126.1% increase from the current price of $14.15.
What is the overall VOR consensus from analysts for Vor Biopharma Inc.?
The overall analyst consensus for VOR is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $46.00.
How accurate are VOR stock price projections?
Stock price projections, including those for Vor Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 4:02 AM UTC